BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hussein A, Guevara CA, Del Valle P, Gupta S, Benson DL, Huntley GW. Non-Motor Symptoms of Parkinson's Disease: The Neurobiology of Early Psychiatric and Cognitive Dysfunction. Neuroscientist 2021;:10738584211011979. [PMID: 33966533 DOI: 10.1177/10738584211011979] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
Number Citing Articles
1 Lee J, Wang Z, Moscatello A, Kingsbury C, Cozene B, Farooq J, Saft M, Sadanandan N, Gonzales-portillo B, Zhang H, Salazar FE, Toledo ARL, Monroy GR, Berlet R, Sanberg CD, Sanberg PR, Borlongan CV. Inflammatory gut as a pathologic and therapeutic target in Parkinson’s disease. Cell Death Discov 2022;8. [DOI: 10.1038/s41420-022-01175-2] [Reference Citation Analysis]
2 Poirier AA, Côté M, Bourque M, Jarras H, Lamontagne-Proulx J, Morissette M, Paolo TD, Soulet D. DIFFERENTIAL CONTRIBUTION OF ESTROGEN RECEPTORS TO THE INTESTINAL THERAPEUTIC EFFECTS OF 17β-ESTRADIOL IN A MURINE MODEL OF PARKINSON'S DISEASE. Brain Res Bull 2022:S0361-9230(22)00163-0. [PMID: 35781029 DOI: 10.1016/j.brainresbull.2022.06.019] [Reference Citation Analysis]
3 Yang R, Gao G, Yang H. The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease. Front Aging Neurosci 2022;14:861035. [DOI: 10.3389/fnagi.2022.861035] [Reference Citation Analysis]
4 Zhang M, Li C, Ren J, Wang H, Yi F, Wu J, Tang Y. The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson’s Disease. Front Aging Neurosci 2022;14:909303. [DOI: 10.3389/fnagi.2022.909303] [Reference Citation Analysis]
5 Iarkov A, Mendoza C, Echeverria V. Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease. Front Neurosci 2021;15:665820. [PMID: 34616271 DOI: 10.3389/fnins.2021.665820] [Cited by in F6Publishing: 3] [Reference Citation Analysis]